Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Julia E. McGuinness"'
Autor:
Meghna S. Trivedi, Melissa K. Accordino, Fabio M. Iwamoto, Deanna Fisher, Lan Huynh, Kathleen Fenn, Julie Ann Mayer, Kevin Kalinsky, Dawn L. Hershman, Julia E. McGuinness, David Cieremans, Edgar V. Sales, Mary Welch, Margaux Wooster, Robbie Schultz, Shing Lee, Lauren Franks, Teri N. Kreisl, Andrew B. Lassman, Katherine D. Crew, Veena M. Singh, Aya Haggiagi
Publikováno v:
Clin Breast Cancer
Diagnosis of LM is limited by low sensitivity of cerebrospinal fluid (CSF) cytopathology. Detecting tumor cells in CSF (CSF-TCs) might be more sensitive. We evaluated if CNSide (CNSide), a novel assay for tumor cell detection in CSF, can detect CSF-T
Autor:
Vicky Ro, Donna Russo, Julia E. McGuinness, Meghna S. Trivedi, Ilana Chilton, Boya Guo, Wendy K. Chung, Rita Kukafka, Tarsha Jones, Katherine D. Crew, Elana Levinson, Carrie Koval, Roshni Rao
Publikováno v:
JCO Oncol Pract
PURPOSE: Increasing usage of multigene panel testing has identified more patients with pathogenic or likely pathogenic (P or LP) variants in low-moderate penetrance genes or variants of uncertain significance (VUS). Our study evaluates the associatio
Autor:
Katherine D. Crew, Melissa K. Accordino, Alessandro Marone, Shing M. Lee, Lauren Franks, Andreas H. Hielscher, Kevin Kalinsky, Julia E. McGuinness, Dawn L. Hershman, Mirella L. Altoe, Meghna S. Trivedi, Mariella Tejada, Hyun K. Kim
Publikováno v:
Breast Cancer Research and Treatment. 189:297-304
Diffuse optical tomography breast imaging system (DOTBIS) non-invasively measures tissue concentration of hemoglobin, which is a potential biomarker of short-term response to neoadjuvant chemotherapy. We evaluated whether DOTBIS-derived measurements
Publikováno v:
Breast Cancer Research and Treatment. 189:1-13
While checkpoint inhibitors have been approved in patients with newly metastatic PDL1-positive triple negative breast cancer, similar clinical benefit with immunotherapy alone or in combination with chemotherapy has not been observed in patients with
Autor:
Simukayi Mutasa, Julia E. McGuinness, Richard Ha, Katherine D. Crew, Jana Lee, Aishwarya Anuraj
Publikováno v:
Cancer Research. 81:PS5-21
Background: The standard of care for early-stage hormone receptor (HR)-positive breast cancer is 5-10 years of adjuvant endocrine therapy (ET), which is associated with a 50-60% relative risk reduction in breast cancer recurrence. However, patients r
Autor:
Julia E. McGuinness, Tarsha Jones, Elana Levinson, Donna Russo, Wendy K. Chung, Carrie Koval, Ilana Chilton, Meghna S. Trivedi, Boya Guo, Roshni Rao
Publikováno v:
Cancer Research. 80:P6-08
Background: Contralateral prophylactic mastectomy (CPM) is a risk-reducing surgery offered to women with unilateral breast cancer intended to reduce the risk of contralateral breast cancer. The rate of CPM among women with unilateral early-stage brea
Autor:
Julia E. McGuinness, Kevin Kalinsky
Publikováno v:
Expert opinion on biological therapy. 21(7)
Metastatic triple-negative breast cancers (mTNBC) are characterized by aggressive behavior and worse clinical outcomes than other breast cancer subtypes, as well as poor response to cytotoxic chemotherapies. The use of antibody-drug conjugates (ADCs)
Autor:
Katherine D. Crew, Julia E. McGuinness
Publikováno v:
Journal of cancer treatment & diagnosis
Screening mammography is recommended by U.S. medical organizations for breast cancer screening in average risk women because of its demonstrated reductions in breast cancer mortality. However, significant disparities in breast cancer screening utiliz
Autor:
Jennifer Vargas, Julia E. McGuinness, Rossy Sandoval, Hae Seung Yi, Alejandro Vanegas, Raven David, Meghna S. Trivedi, Rita Kukafka, Katherine D. Crew, William Ueng
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 27:446-453
Background: Potential harms of screening mammography include false positive results, such as recall breast imaging or biopsies. Methods: We recruited women undergoing screening mammography at Columbia University Medical Center in New York, New York.
Autor:
Julia E. McGuinness, Vicky Ro, Simukayi Mutasa, Aishwarya Anuraj, Haley Manley, Richard Ha, Katherine D. Crew
Publikováno v:
Clinical Cancer Research. 27:PR-04
Background: Chemoprevention with anti-estrogens such as tamoxifen has been shown to lower mammographic density (MD), a strong predictor of breast cancer risk. However, measurement of MD is limited by variability in radiologists’ interpretations. We